For instance, all esophagogastric cancer samples have TP53 mutations, whereas 85% of pancreatic cancer samples have KRAS mutations, and 85% of the pilocytic astrocytoma samples have BRAF mutations. This evidence concerns the gene KRAS and pancreatic neoplasm.